Listed by the USPTO as BAZARGANI, ARYA AHMADI
Tech Center 3700 • Art Units: 1600 1611 1613 1614 1615 1625 3774
This examiner grants 62% of resolved cases
BAZARGANI, ARYA AHMADI has 8 resolved cases in Tech Center 3700 and Art Unit 1600. The allowance rate is 62.5%, and the median time to allowance is 951 days. The small resolved docket limits the breadth of the profile, so these figures provide an initial signal rather than an extensive historical pattern.
The interview lift is 31.3%, indicating that interviews are associated with a meaningful change in outcomes in the available cases. The leading companies are The Regents of the University of California, Merck Patent GmbH, and BASF SE. The leading firms are MARSHALL, GERSTEIN & BORUN LLP, ROTHWELL, FIGG, ERNST & MANBECK, P.C., and BakerHostetler.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18769141 | TOPICAL ANALGESICS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17423592 | METHOD FOR MANUFACTURING A SOLID ADMINISTRATION FORM AND SOLID ADMINISTRATION | Non-Final OA | MERCK PATENT GMBH |
| 18681909 | AGROCHEMICAL COMPOSITION | Non-Final OA | BASF SE |
| 18719998 | DEVICES CONTAINING PLANT-SUITABLE ACTIVE INGREDIENTS THAT ARE APPLIED TO THE SOIL OR TO THE AERIAL PARTS OF PLANTS | Final Rejection | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18860487 | Drug Releasing Hydrogels, Materials, Devices, and Uses Related Thereto | Non-Final OA | Georgia Tech Research Corporation |
| 17923182 | METHODS FOR SYNTHESIZING ANHYDROUS LACTIC ACID | Non-Final OA | Otsuka Pharmaceutical Co., Ltd. |
| 18715873 | CREAMY COSMETIC COMPOSITION | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18832464 | INJECTABLE FORMULATION CONTAINING ISOXAZOLINE DERIVATIVE | Non-Final OA | LG CHEM, LTD. |
| 18599930 | SKIN CARE COMPOSITIONS | Non-Final OA | Colgate-Palmolive Company |
| 18834306 | CONTROLLED DRUG RELEASE PREPARATION COMPOSITION AND CONTROLLED DRUG RELEASE PREPARATION | Final Rejection | SUMITOMO SEIKA CHEMICALS CO., LTD. |
| 18548690 | ORAL THIN FILM | Final Rejection | LTS LOHMANN THERAPIE-SYSTEME AG |
| 18715607 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | Final Rejection | Spoke Sciences, Inc. |
| 18699241 | ORGANOSULFUR COMPOUNDS AS PLANT BIOSTIMULANTS | Final Rejection | Crop Health Vision B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.5% of resolved applications examined by Arya Ahmadi Bazargani were allowed (8 resolved cases), compared with 36.7% across Art Unit 1600 over the last five years.
This examiner's interview lift is +31.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Arya Ahmadi Bazargani took 951 days on average from filing to allowance.
Arya Ahmadi Bazargani examines applications in Art Unit 1600 in Tech Center 3700 (Medical Devices & Mechanical Engineering).